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Abstract
Anxiety is associated with threat-related biases in information processing such as heightened attentional
vigilance to potential threat. Such biases are an important focus of psychological treatments for anxiety
disorders. Selective serotonin reuptake inhibitors (SSRIs) are eﬀective in the treatment of a range of anxiety
disorders. The aim of this study was to assess the eﬀect of an SSRI on the processing of threat in healthy
volunteers. A selective noradrenergic reuptake inhibitor (SNRI), which is not generally used in the treat-
ment of anxiety, was used as a contrast to assess the speciﬁcity of SSRI eﬀects on threat processing. Forty-
two healthy volunteers were randomly assigned to 7 d double-blind intervention with the SSRI citalopram
(20 mg/d), the SNRI reboxetine (8 mg/d), or placebo. On the ﬁnal day, attentional and interpretative bias to
threat was assessed using the attentional probe and the homograph primed lexical decision tasks.
Citalopram reduced attentional vigilance towards fearful faces but did not aﬀect the interpretation of
ambiguous homographs as threatening. Reboxetine had no signiﬁcant eﬀect on either of these measures.
Citalopram reduces attentional orienting to threatening stimuli, which is potentially relevant to its clinical
use in the treatment of anxiety disorders. This ﬁnding supports a growing literature suggesting that
an important mechanism through which pharmacological agents may exert their eﬀects on mood is by
reversing the cognitive biases that characterize the disorders that they treat. Future studies are needed to
clarify the neural mechanisms through which these eﬀects on threat processing are mediated.
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Introduction
Contemporary cognitive psychology models empha-
size the role that biases in threat processing play in the
aetiology and maintenance of clinical states of anxiety
(e.g. Beck et al., 1985 ; Eysenck, 1992, 1997 ; MacLeod
et al., 2004 ; Mogg and Bradley, 1998 ; Williams et al.,
1988, 1997 ; Yiend and Mackintosh, 2004). Individuals
with high trait anxiety and patients with a range of
clinical anxiety disorders have been shown to have
threat-related biases in selective attention. For ex-
ample, studies using the attentional probe paradigm
have demonstrated that individuals with high levels
of anxiety are relatively faster to respond to probes
that replace threatening stimuli than probes that re-
place neutral stimuli compared with low-anxiety con-
trols, indicating increased attentional vigilance to the
location of the threat stimuli (Koster et al., 2005 ; Mogg
et al., 1994, 1997 ; Yiend and Mathews, 2001). There is
also good evidence that interpretative biases favour-
ing threat also play an important role in a wide range
of anxiety disorders (e.g. Clark et al., 1997 ; Eysenck
et al., 1991; Huppert et al., 2007 ; Stoler and McNally,
1991). For example, when presentedwith a homograph
that has both a threat meaning and a non-threat mean-
ing (such as ‘patient’), individuals with high levels
of trait anxiety and patients with anxiety disorders are
typically faster to report whether a word is a real word
or a non-word in response to an associate of the threat
Address for correspondence : Dr C. J. Harmer, University Department
of Psychiatry, Warneford Hospital, Warneford Lane, Oxford,
OX3 7JX, UK.
Tel. :++44 1865 223961 Fax :++44 1865 251076
E-mail : Catherine.Harmer@psych.ox.ac.uk
International Journal of Neuropsychopharmacology (2009), 12, 169–179. Copyright f 2008 CINP
doi:10.1017/S1461145708009164
ARTICLE
CINP
interpretation (e.g. ‘hospital ’) than an associate of the
neutral interpretation (e.g. ‘calm’) compared with
low-anxious controls (Richards and French, 1992).
Reducing threat-related processing biases is a major
focus of cognitive-behavioural therapeutic inter-
ventions for the treatment of anxiety disorders (Beck
et al., 1985). Recently, evidence has emerged to suggest
that pharmacological treatments for mood disorders
may also inﬂuence emotional processing. For example,
short-term (7 d) administration of the selective sero-
tonin reuptake inhibitor (SSRI), citalopram, and the
selective noradrenaline reuptake inhibitor (SNRI), re-
boxetine, has been shown to reduce the processing of
negative emotional material, such as fearful and angry
faces, and to increase the perception of and memory
for positively valenced emotional material in healthy
volunteers (Harmer et al., 2004). Importantly, these
changes in emotional processing occur in the absence
of signiﬁcant diﬀerences in subjective mood and more
rapidly than the therapeutic eﬀects of these drugs
would typically be seen clinically. This suggests that
antidepressants may directly modulate the neural pro-
cessing of emotional and social information, rectifying
the maladaptive processing biases seen in depression.
This may represent an important mechanism by which
these pharmacological agents exert their therapeutic
eﬀects.
Given the growing evidence of the therapeutic
value of SSRIs in the treatment of a range of anxiety
disorders (Dhillon et al., 2006 ; Kent et al., 1998 ; Pae
and Patkar, 2007), an outstanding question is whether
SSRIs have eﬀects on emotional processing biases that
are particularly relevant to anxiety. There is some evi-
dence from clinical studies to support this notion. For
example, Mogg and colleagues (2004) reported that
patients with generalized anxiety disorder produced
signiﬁcantly fewer threat-related spellings of homo-
phones following 4 wk treatment with a SSRI com-
pared to before treatment. Furthermore, this reduction
in threat-related interpretative bias was positively
correlated with clinical improvement, suggesting that
it was relevant to the therapeutic action of the drug.
The major diﬃculty with interpreting such eﬀects,
however, is that it is not possible to distinguish the
direct action of the drug on threat processing from
non-speciﬁc eﬀects of symptom change produced by
the SSRI treatment. Assessment of the cognitive eﬀects
of short-term antidepressant administration to healthy
volunteers is one method of circumventing this prob-
lem, as it allows the direct eﬀect of the drug to be
assessed in the absence of symptom change and in
comparison with a placebo control group. The current
study therefore assessed the eﬀect of a SSRI on
anxiety-related emotional processing paradigms in
healthy volunteers.
Unlike SSRIs, selective noradrenaline reuptake in-
hibitors (SNRIs), while eﬀective antidepressants, are
not commonly used in the treatment of anxiety. Con-
sistent with this, we have previously reported that
whilst both of these classes of antidepressants posi-
tively bias emotional processing, they have a diﬀerent
proﬁle of eﬀects on response to threat as measured
by the emotion-potentiated startle response (Harmer
et al., 2004). Thus, while 7 d citalopram administration
reduces the potentiation of the startle response by
negative pictures in healthy volunteers, reboxetine has
no eﬀect on this paradigm (Harmer et al., 2004). On the
basis of this, we have previously hypothesized that
whilst citalopram inﬂuences emotional processing
biases that are relevant to both anxiety and depression,
the eﬀect of reboxetine is expressed more speciﬁcally
on the elaborative and explicit processes that are par-
ticularly implicated in depression. In order to test this
hypothesis, a reboxetine-treated group was included
in the present study as an additional contrast.
The current study therefore assessed the eﬀect of
7 d treatment with the SSRI, citalopram, and the SNRI,
reboxetine, on anxiety-related threat processing para-
digms in healthy volunteers. This treatment period
was chosen because, as mentioned above, 7 d admin-
istration of antidepressants to healthy volunteers has
previously been shown to have signiﬁcant eﬀects on
emotional processing (Harmer et al., 2004). A 7-d treat-
ment period also has the particular advantage of al-
lowing the eﬀects of the drug on emotional processing
to be measured before the full therapeutic eﬀect would
typically be seen in clinical populations. Threat pro-
cessing was assessed with a commonly used test
of attentional vigilance to threat (the attentional probe
task, using emotional facial expressions as stimuli) and
a commonly used test of interpretative bias (the
homograph primed lexical decision task). It was pre-
dicted that citalopram would reduce attentional and
interpretative threat-relevant biases compared with
placebo but that reboxetine would have no eﬀect on
these anxiety-related emotional processing paradigms.
Methods
A total of 42 (20 male, 22 female) volunteers took part
in the study. Participants were recruited through
adverts in University departments and screened to
exclude those with a current or previous history of
psychiatric disorder [assessed using the Structured
Clinical Interview for DSM-IV (SCID)] ; history of
alcohol or other substance abuse or dependence
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(assessed using SCID criteria) ; pregnancy or lactation ;
history of signiﬁcant medical disorder ; and current
usage of any medication other than oral contraception.
Four (three citalopram group, one reboxetine group)
of the participants were occasional smokers (deﬁned
as <2 cigarettes per day). All participants gave their
written informed consent to participate in the study,
which was approved by Oxfordshire Research Ethics
Committee in accordance with the ethical standards
laid down in the 1964 Declaration of Helsinki.
Volunteerswere randomly allocated to double-blind
intervention with one of the three following oral treat-
ments for a period of 7 d: placebo, citalopram (20 mg/
d) or reboxetine (4 mg b.i.d.). Medication was given in
identical capsules twice a day to maintain blinding.
The three groups were matched in terms of gender,
verbal IQ (assessed with the National Adult Reading
Test) and age (see Table 1). Participants were asked to
refrain from drinking alcohol during the study week
andwere not allowed to drink caﬀeine or smoke during
the test session on day 7. Testing did not take place
during female participants’ premenstrual week.
Subjective mood was recorded before and on day 7
of treatment using the following questionnaires : State-
Trait Anxiety Inventory (Spielberger et al., 1983),
Buss–Durkee Hostility Inventory (Buss and Durkee,
1957), Dysfunctional Attitudes Scale (Weisman and
Beck, 1978). On day 7 of intervention, participants
completed the attentional probe task and the homo-
graph primed lexical decision task.
Attentional probe task
Pairs of photographs of 20 individuals were taken
from the JACFEE/JACNeuF sets of facial expressions
(Matsumoto and Ekman, 1988). Each face pair com-
prised one emotional and one neutral expression of
the same individual or two neutral expressions of the
same individual. Half of the emotional faces were
fearful and half were happy. Thus, there were three
types of face pairs : neutral-neutral, fearful-neutral and
happy-neutral. On each trial, one of the faces appeared
above and the other below the central ﬁxation pos-
ition. The task was fully counterbalanced for emotion
location, probe location and probe type. In the un-
masked condition, the face pair was presented for
100 ms and was immediately followed by a probe,
which appeared in the location of one of the preceding
faces. The probe was two dots presented either verti-
cally ( :) or horizontally (. .). Participants were required
to report the orientation of the dots by pressing a
labelled key on a keyboard. The dots remained on
the screen until participants had made their response.
Participants were asked to respond as quickly and as
accurately as possible. The sequence of events was the
same in the masked condition, except the face pair was
displayed for 16 ms and followed by a mask (construc-
ted from a jumbled face), which was displayed for
84 ms.
The timing of the masked and unmasked condition
was decided based upon the results of a pilot study.
It was important to identify timings that produced
attentional vigilance eﬀects to the fearful faces in
healthy, low anxious volunteers, in order to be able to
investigate whether citalopram reduces such vigilance.
In the pilot study, eight healthy, unmedicated volun-
teers completed a masked and unmasked version of
the task, each with two timing conditions (masked:
16 ms target, 84 ms mask and 16 ms target, 234 ms
mask; unmasked: 100 ms target and 250 ms target).
Consistent with a previous study using angry faces in
a dot probe paradigm (Cooper and Langton, 2006), the
100-ms unmasked condition produced signiﬁcant at-
tentional vigilance eﬀects towards the fearful faces
compared with neutral, whereas there was no signiﬁ-
cant attentional vigilance to the fearful faces in the
250-ms target unmasked condition. Similarly, the
shorter of the two masked timing conditions (16 ms
target, 84 ms mask) but not the longer produced sig-
niﬁcant attentional vigilance eﬀects towards the fear-
ful faces.
There were 192 trials in total (masked: 32 happy-
neutral, 32 fear-neutral, 32 neutral-neutral ; unmasked:
32 happy-neutral, 32 fear-neutral, 32 neutral-neutral).
There were eight blocks of unmasked trials (12 trials
per block) and eight blocks of masked trials (12 trials
per block) which were presented in an alternating or-
der with an ABAB design.
Table 1.Demographic characteristics of 42 healthy volunteers
randomly assigned to 7 d intervention with citalopram,
reboxetine or placebo. There were no signiﬁcant diﬀerences
between the three groups on any of these measures
Placebo Citalopram Reboxetine
Females Males Females Males Females Males
Total in
group
(n=8) (n=6) (n=8) (n=6) (n=7) (n=7)
Age (yr) 25.75 23 23.1 25.3 24.9 23.4
(5.3) (1.7) (3.1) (2.5) (2.4) (2.1)
Verbal
IQ
117.6 120.1 114.4 118 116.4 120.7
(4.8) (5.8) (3.8) (6.0) (3.5) (3.7)
Values represent the mean with the standard deviation in
parentheses.
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Trials with response times off100 ms, oro2000 ms
were excluded from the analysis. The mean percent-
age of data lost due to reaction time outliers was
0.16%. Attentional vigilance scores were calculated for
each participant by subtracting the mean reaction time
from trials when probes appeared in the same position
as the emotional word (congruent trials) from trials
when probes appeared in the opposite position to the
emotional word (incongruent trials). Positive values
reﬂect attention towards the emotional face (vigilance)
and negative values reﬂect attention away from the
emotional face (avoidance).
Threat/neutral homograph and lexical decision
making task
Eighty threat/neutral homographs were selected from
the norms compiled by French and Richards (1992) to
be used as primes. Each homograph had two primary
meanings, which diﬀered signiﬁcantly in threat value,
as rated by 12 independent judges (see French and
Richards, 1992 for details). For each homograph, a
word associated with the threat meaning and a word
associated with the neutral meaning was selected to be
used as the related targets. These were generally the
most common word associated with each meaning,
however, occasionally an alternative word was selec-
ted in order to avoid repetition and to help matching.
Each prime was also paired with a semantically un-
related target from both the threat set and the neutral
set. This procedure was carried out by one exper-
imenter (K.L.) and independently veriﬁed by a second
experimenter (S.M.). The neutral and threat targets
were matched for word length and association
strength. Forty of the homograph primes were used in
word trials and the other half were used on non-word
trials with a set assignment that was counterbalanced
across participants. The procedure for creating the
non-word pairings was the same as described above
with the addition of an extra step in which one of
the letters of each of the target words was changed
in order to produce a pronouncable non-word. Each
homograph was only presented once and followed by
a non-word target (40 trials) or one of four possible
word targets : related neutral target (10 trials), related
threat target (10 trials), unrelated neutral target (10
trials), unrelated threat target (10 trials).
On each trial, a ﬁxation cross was presented for 2 s,
followed by a homograph prime which was presented
in lower-case letters in the middle of the screen for
750 ms. Immediately following the prime, the word or
non-word target was displayed in upper-case letters
on the screen and participants were required to press
one of two keys on the keyboard to indicate whether
the word was a legitimate English word or not. The
target remained on the screen until volunteers had
made their response and the timing of responses began
with the presentation of the target. Participants com-
pleted four practice trials prior to the experimental
trials in order to familiarize themselves with the task
procedure. There was an untimed rest period halfway
through the task in order to minimize fatigue.
Statistical analyses
Data were analysed using split-plot two-way analyses
of variance (ANOVAs). For all ANOVAs, treatment
group (citalopram, reboxetine or placebo) was the
between-subjects factor. The within-subjects factors
were : emotion and time (subjective mood scales) ; face
valence and masking (attentional probe task) ; target
valence and trial type (homograph task). Gender was
also initially entered as a between-subjects factor.
However, if the main eﬀect of gender and interactions
of gender and treatment group were found to be non-
signiﬁcant, data were collapsed across gender for
subsequent analyses. Where necessary, the interpret-
ation of signiﬁcant eﬀects was aided by the use of
simple main-eﬀect analyses. Where assumptions of
equality of variances were broken, the Greenhouse–
Geisser procedure was used to correct the degrees
of freedom.
Results
Subjective mood, anxiety and hostility
There were no signiﬁcant eﬀects of treatment group
on any of the measures of subjective mood, anxiety
or hostility (see Table 2).
Attentional probe task
Accuracy rates were very high in this task (placebo,
mean 94%; citalopram, mean 92%; reboxetine, mean
92%) and there were no signiﬁcant eﬀects of treatment
group on accuracy across any of the task conditions
(all comparisons, p>0.2). Data from trials with errors
were therefore discarded and not analysed further.
There was no signiﬁcant eﬀect of treatment group on
average overall reaction times or on reaction times on
the neutral-neutral trials (all p values >0.2), suggest-
ing no baseline reaction time diﬀerences between
the three groups. An ANOVA was performed on the
attentional vigilance scores with two between-subjects
factors (treatment group and gender) and two within-
subjects factors (face valence and masking). This
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revealed a signiﬁcant main eﬀect of valence [F(1, 36)=
4.797, p=0.035], which reﬂected signiﬁcantly greater
attentional vigilance towards the fearful faces than the
happy faces. There was no signiﬁcant three-way in-
teraction between grouprvalencermasking status.
However, there was a signiﬁcant interaction between
group and masking status [F(2, 36)=4.402, p=0.019].
In order to investigate this in more detail, attentional
vigilance in each masking condition was analysed sep-
arately. In the masked condition there were no sig-
niﬁcant eﬀects of valence or group on attentional
vigilance (all p values >0.2). However, in the un-
masked condition, there was again a signiﬁcant eﬀect
of valence [F(1, 39)=7.312, p=0.01] reﬂecting relatively
greater attentional bias to the fearful faces than the
happy faces across all groups (see Figure 1). There was
also a signiﬁcant main eﬀect of group [F(2, 39)=3.704,
p=0.03]. Post-hoc least signiﬁcant diﬀerence compari-
sons revealed that signiﬁcant diﬀerences between
the placebo and the citalopram group (p=0.02) and
between the citalopram and reboxetine groups
(p=0.03) were driving this main eﬀect. There was
no signiﬁcant diﬀerence between the placebo and
reboxetine groups (p=0.9). It can be seen from Figure 1
that these diﬀerences were mainly driven by a
decrease in attentional vigilance to fearful faces in
the citalopram group compared with the placebo and
reboxetine groups. Group diﬀerences on attentional
vigilance measures do not indicate which of the
groups is exhibiting an absolute bias (see Gotlib et al.,
1988). To clarify this, one-sample t tests were used to
compare attentional bias scores to zero within each
group. These analyses revealed that the placebo and
Table 2. Subjective state ratings before and after 7 d treatment with placebo, citalopram or reboxetine. There were no
signiﬁcant eﬀects of treatment group on any of the measures
Measure
Score
Placebo (n=14) Citalopram (n=14) Reboxetine (n=14)
Before
treatment
After
treatment
Before
treatment
After
treatment
Before
treatment
After
treatment
Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D.
State-Trait Anxiety Inventory
State Anxiety 31.5 7.4 32.6 10.6 32.9 8 32 9.8 31.5 7.3 29 6.28
Trait Anxiety 32.4 7 34 10.1 33.1 6.7 33.6 7.2 29 4.8 29.7 5.6
Buss–Durkee Hostility Inventory 22.5 5.7 21.1 6.6 24.9 5.4 25.6 7.5 23.8 11.6 23.4 11.5
Dysfunctional Attitudes Scale 114.6 22.8 113.2 27.1 128.2 24.8 130.4 25.1 114.4 33.3 114 30.1
Values represent mean and standard deviation (S.D.).
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Figure 1.Attentional vigilance in the attentional probe task in
(a) the masked condition and (b) the unmasked condition.
Vigilance is calculated by subtracting mean reaction time to
respond when probe replaces emotional face (fearful or
happy) from the reaction time when the probe replaces the
neutral face. Thus the higher the vigilance score, the greater
the attentional bias towards the emotional face. Error bars
represent standard error of mean (* p<0.05 for comparison
between citalopram and placebo groups and between
reboxetine and citalopram groups).%, Placebo ;
, citalopram;&, reboxetine.
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reboxetine groups both showed a signiﬁcant bias
towards fearful faces [placebo: t(13)=2.502, p=0.027;
reboxetine : t(13)=2, 218, p=0.045]. In contrast, the
citalopram group showed no signiﬁcant bias to fearful
faces [t(13)=0.023, p=0.982]. None of the three treat-
ment groups showed a signiﬁcant bias towards happy
faces (all p values >0.1). Attentional vigilance scores
on this task were not signiﬁcantly aﬀected by gender
and there were no signiﬁcant interactions between
gender and treatment group (all p values>0.09).
Homograph primed lexical decision task
Data from one volunteer (citalopram group) is missing
due to technical diﬃculties. There was no signiﬁcant
eﬀect of treatment group on accuracy in this task
[F(1, 38)=0.363, p=0.7] and no signiﬁcant interaction
between target valence and treatment group [F(2, 38)=
0.405, p=0.670]. Trials with errors were therefore dis-
carded and not included in any further analyses. An
ANOVA was performed on the mean reaction times
for correct responses to word targets presented fol-
lowing threat/neutral primes. This analysis had two
between-subjects factors (treatment group and gender)
and two within-subjects factors ; target valence (threat
vs. neutral) and target type (related vs. unrelated).
This revealed a signiﬁcant main eﬀect of target type
[F(1, 36)=28.83, p<0.001] and a signiﬁcant interaction
between target valence and target type [F(1, 36)=4.96,
p=0.032]. As can be seen from Table 3, across all
treatment groups and both target valences, volunteers
were signiﬁcantly faster to respond to targets that were
related to the prime compared to targets that were
unrelated to the prime. This facilitation eﬀect was
more pronounced for threat than neutral targets.
However, there were no signiﬁcant eﬀects of treatment
group on this pattern (p>0.2 for all comparisons).
Reaction times on this task were not signiﬁcantly
aﬀected by gender and there were no signiﬁcant in-
teractions between gender and treatment group (all
p values>0.1).
Discussion
This study examined the eﬀect of 7 d treatment with
two diﬀerent classes of antidepressant drugs on threat
processing in healthy volunteers. The ﬁndings suggest
that short-term administration of the SSRI citalopram
reduces attentional vigilance towards emotional faces
but does not aﬀect the interpretation of ambiguous
homographs as threatening. As predicted, the SNRI,
reboxetine, did not have any signiﬁcant eﬀects on
either of these measures of biases in the processing
of threat.
Citalopram and attentional vigilance to emotional
faces
Citalopram administration reduced attentional vigil-
ance to emotional faces independently from valence,
reﬂected in a signiﬁcant main eﬀect of treatment group
on the attentional probe paradigm. Further analyses
suggested that this eﬀect was primarily driven by
reduced attentional vigilance to fearful faces. Whilst
both the placebo group and the reboxetine group
showed a signiﬁcant bias towards fearful faces, this
was abolished in the citalopram group. There is a
considerable body of empirical data demonstrating
heightened attentional vigilance towards threatening
stimuli in individuals with high levels of trait anxiety
and individuals with a range of clinical anxiety dis-
orders (Koster et al., 2005 ; MacLeod et al., 1986; Mogg
and Bradley, 2002 ; Yiend and Mathews, 2001). It has
been suggested that these cognitive biases may play an
important role in the maintenance, and possibly even
the underlying aetiology, of anxiety (e.g. MacLeod
et al., 2002, 2004; Mathews and MacLeod, 1994 ; Yiend
and Mackintosh, 2004). Such biases are a major
focus of cognitive behavioural therapy for anxiety
disorders and there is evidence that threat-related
cognitive biases are reduced following successful
psychological intervention (e.g. Mathews et al., 1995).
The present study suggests that SSRIs may similarly
act to reduce attentional biases towards threat through
a pharmacological mechanism. Furthermore, given
that these eﬀects were seen in healthy volunteers in the
absence of any signiﬁcant changes in mood or anxiety,
Table 3. Reaction times for threat and neutral targets
following the presentation of a threat/neutral homograph
prime in the homograph primed lexical decision task
Threat/neutral
prime Placebo Citalopram Reboxetine
Threat target
Related (R) 649.8 (46.9) 632.5 (32) 654.3 (41.9)
Unrelated (U) 773.5 (72.2) 732.7 (61.5) 742.3 (47.6)
Diﬀerence UxR +123.7 (39.3) +100.2 (32.5) +88 (41.6)
Neutral target
Related (R) 648 (42.6) 679 (47.5) 645.6 (35.8)
Unrelated (U) 728.2 (47.5) 720.5 (50) 702.8 (44.3)
Diﬀerence UxR +80.3 (17.4) +41.5 (16.8) +57.2 (26.3)
Values represent mean with standard error of the mean in
parentheses.
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the current ﬁndings suggest that reduced attentional
vigilance to threatening environmental stimuli may
represent a direct eﬀect of serotonergic antidepressant
administration, seen relatively early in treatment, and
which may be relevant to the therapeutic actions of
this pharmacological agent.
Several models suggest that anxiety biases attention
towards threat-related stimuli by increasing the out-
put from an amygdala-centred threat evaluation sys-
tem (Mathews and Mackintosh, 1998 ; O¨hman and
Wiens, 2004). This hypothesis is supported by a range
of neuroimaging studies indicating hyperarousal of
the amygdala in anxiety disorders both at rest and in
response to threat-relevant stimuli (Birbaumer et al.,
1998 ; Liberzon et al., 1999 ; Mathews et al., 2004 ;
Rauch et al., 1996, 2000 ; Semple et al., 2000; Shin et al.,
1997). Such a proposal is also consistent with evidence
from animal and human studies suggesting that the
amygdala is critically involved in the fast, automatic
appraisal of threat stimuli and directing attention to-
wards emotionally salient, biologically relevant events
(Davis and Whalen, 2001 ; LeDoux, 1995). In line with
the dense serotonergic innervation of the amygdala,
it seems reasonable to suggest that the SSRI eﬀects
on attentional vigilance to threat seen in the present
study may be mediated through interactions with this
circuitry. In support of this notion, 7 d administration
of citalopram to healthy volunteers has recently been
shown to reduce the amygdala response to masked
presentations of fearful faces (Harmer et al., 2006).
There is a growing body of evidence to suggest
that the attentional biases in threat processing seen
in anxiety do not necessarily depend on conscious
awareness of the emotional stimuli. For example, in an
attentional probe paradigm anxious individuals have
been shown to orient to the position of previously
presented threat-related stimuli, even when they were
backwardly masked and therefore presented below
the level of conscious awareness (Mogg et al., 1995b).
Such preconscious attentional biases to threat have
been shown to be reduced following cognitive behav-
ioural therapy (e.g. Mogg et al., 1995a). However,
contrary to predictions, there was no signiﬁcant eﬀect
of citalopram on attentional vigilance to masked fear-
ful faces in the present study. There are two potential
methodological limitations in the task design that may
have contributed to this lack of eﬀect. First, the atten-
tional vigilance to the fearful faces in the placebo
group was less marked in the masked condition com-
pared to the unmasked condition and therefore the
power to detect a modulation of this bias in the citalo-
pram group may have been insuﬃcient. Second, no
assessment of awareness of the masked stimuli was
carried out. The threshold for the detection of back-
wardly masked stimuli has been shown to be depen-
dent on a number of factors, including the particular
discrimination task used and individual diﬀerences.
For example, Mogg and Bradley (1999) note that if
stimuli are presented very close to awareness thresh-
olds, the pre-attentive eﬀects of masked stimuli may be
reduced. Therefore, any degree of variability between
the treatment groups in the present study in terms of
the threshold for awareness of the masked stimuli may
have confounded the eﬀect of the drug treatment on
attentional vigilance to these stimuli.
It should be noted that it is diﬃcult to draw any
conclusions about the eﬀect of citalopram on atten-
tional vigilance to happy faces from the present study,
since there was no signiﬁcant bias eﬀect in the placebo
group. The primary aim of the present study was to
examine the eﬀect of citalopram on selective attention
to threat-related stimuli and the timings of the atten-
tional probe paradigm were therefore selected (on
the basis of pilot data) to ensure a robust attentional
bias towards fearful faces in the placebo group.
Consistent with a previous report using angry faces, it
was found that a short stimulus presentation time of
100 ms produced a robust attentional vigilance eﬀect
towards threat-related face stimuli in healthy volun-
teers (Cooper and Langton, 2006). It may be, however,
that attentional vigilance towards positive stimuli is
better studied using longer stimulus presentation
times. In support of this, Cooper and Langton (2006)
report opposite patterns of vigilance and avoidance
for happy and angry faces across presentation times.
They report a bias towards angry faces at 100 ms fol-
lowed by a signiﬁcant bias away from angry faces
at 500 ms. Conversely, they found a signiﬁcant bias
away from the happy faces at 100 ms and a bias to-
wards happy faces at 500 ms. Further studies are
needed to investigate the eﬀects of antidepressants
on the processing of positively valenced emotional
material and how this may diﬀer from threat-related
processing.
Citalopram and threat-related interpretative biases
Contrary to predictions, we found no eﬀect of citalo-
pram on the interpretation of ambiguous homographs.
All three treatment groups showed faster responses to
targets that were related to the homograph primes,
indicating that the priming was eﬀective. In addition,
the three groups all showed a relatively increased
priming eﬀect for the threat-related primes compared
with the neutral-related primes, suggesting a threat-
related interpretative bias that was not modulated by
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antidepressant treatment. The lack of eﬀect of citalo-
pram on this task contrasts with a previous report
of reduced threat-related spellings of homophones
following 4 wk citalopram treatment in a group of
patients with generalized anxiety disorder (Mogg
et al., 2004). This previous study did not have a
placebo control group so it is possible that the post-
treatment reduction in threat-related interpretative
bias reﬂects practice eﬀects rather than a speciﬁc eﬀect
of the drug on interpretation. A more interesting ex-
planation for the divergent ﬁndings relates to the
longer SSRI treatment period (4 wk) used in the pre-
vious study compared to the present study (1 wk).
Whilst the early eﬀects of SSRIs may relate speciﬁcally
to selective attention to threat, over time it is possible
that they may generalize to inﬂuence a broader spec-
trum of emotional and social processing. Future
studies are needed to assess how the eﬀects of anti-
depressants on emotional processing change with re-
peated administration.
Reboxetine and threat processing
As predicted, the noradrenergic antidepressant rebox-
etine did not signiﬁcantly aﬀect attentional vigilance
to threat or the threat-related interpretation of am-
biguous homographs. This is consistent with a pre-
vious study in which both citalopram and reboxetine
were shown to enhance the processing of positive vs.
negative information on a number of tasks that tapped
into processes relevant to the cognitive biases seen
in depression (such as emotional memory and the
recognition of facial expressions) but only citalopram
modulated responses on the emotion-potentiated
startle task, a paradigm known to be particularly rel-
evant to fear and anxiety processes (Harmer et al.,
2004). A lack of eﬀect of reboxetine on attentional
vigilance to threat-related stimuli is also in line with
the limited clinical usage of this drug in the treatment
of anxiety compared with citalopram. Indeed, UK
guidelines on the treatment of anxiety disorders rec-
ommend pharmacological treatment with SSRIs and
tricyclic antidepressants, but do not recommend treat-
ment with SNRIs, such as reboxetine (NICE, 2007).
Such concordance between the eﬀects of these drugs on
speciﬁc emotional processes and their clinical usage
lends further support to the therapeutic relevance of
the neuropsychological eﬀects seen. It should be noted,
however, that there is some evidence that reboxetine
is eﬀective in the treatment of some anxiety disorders,
in particular panic disorder, and this distinction is
therefore not absolute (e.g. Seedat et al., 2003 ; Versiani
et al., 2002).
The use of healthy volunteers
Studying the mechanisms of antidepressant drugs in
healthy volunteers has the advantage that the behav-
ioural eﬀects of the drugs can be explored uncon-
founded by changes in clinical state or symptom
remission. Consistent with our previous studies, we
found no signiﬁcant eﬀect of citalopram or reboxetine
on mood or subjective state, as measured by self-
report scales (Harmer et al., 2003a,b, 2004). This sug-
gests that the observed changes following drug
administration represent direct eﬀects of the drugs on
emotional and threat processing rather than a sec-
ondary consequence of mood improvement. However,
it is important to note that the participants used in
this study were generally young, high-functioning
students. Whilst the homogeneity of this sample has
the advantage of increasing the power to detect drug-
related diﬀerences between treatment groups, this re-
stricted demographic proﬁle is not typical of the whole
spectrum of depressed and anxious clinical popu-
lations. Clearly it is necessary to assess whether simi-
lar eﬀects occur following drug treatment in depressed
and anxious patients and whether such early eﬀects
on emotional processing are predictive of eventual
therapeutic eﬃcacy.
Limitations
There are a number of limitations to the present study
that must be considered. First, we did not have a
physiological measure of compliance with the drug
treatment. However, the signiﬁcant eﬀects of citalo-
pram on emotional processing make it likely that
there was good compliance with the treatment in,
at least, the majority of participants. Second, the use
of a between-subjects design has the disadvantage of
variability across the treatment groups generated by
individual diﬀerences. A cross-over design was not
used in this study because of the considerable order
eﬀects that can be seen in emotional processing para-
digms. Indeed, data from our laboratory has consist-
ently indicated that the eﬀects of antidepressants on
emotional processing are strongest on the ﬁrst test
session (C. Harmer, unpublished observations). Con-
sistent with this, it is well established that the habitu-
ation of neural responses to repeated exposure to
stimuli is particularly pronounced in response to
stimuli with an emotional valence. In particular, a
range of studies have demonstrated that the amygdala
rapidly habituates to repeated presentations of
emotional faces (Breiter et al., 1996 ; Whalen et al.,
1998 ; Wright et al., 2001) and pictures (Fischer et al.,
2000 ; Irwin et al., 1996). Animal studies using the
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acoustic startle response as an indirect measure of
amygdala function suggest that such habituation
eﬀects are not just seen within sessions but can also
persist across testing sessions (e.g. Stevenson and
Gratton, 2004). For this reason, all of the participants
in this study were naive to the experimental stimuli
used. However, the between-subjects design did
necessitate careful matching of the groups on a range
of factors (such as age, gender, baseline subjective
mood ratings) in order to ensure internal validity.
Finally, SSRIs are known to have complex interactions
with a number of diﬀerent neurotransmitter systems,
including the noradrenergic and dopaminergic sys-
tems. It is therefore not possible to conclude that the
eﬀects of citalopram on threat processing seen in the
present study are directly mediated by an increase in
serotonin.
Conclusions
In summary, the present study demonstrated that
citalopram reduces attentional orienting to threaten-
ing stimuli, which is highly relevant to its clinical use
in the treatment of anxiety disorders. This ﬁnding
supports a growing literature suggesting that an im-
portant mechanism through which pharmacological
agents may exert their eﬀects on mood is by reversing
the cognitive biases that characterize the disorders that
they treat. Future studies are needed to clarify the
neural mechanisms through which these eﬀects on
threat processing are mediated.
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